Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

6 Recommendations for research

6.1 The committee was aware that an ongoing randomised controlled trial, FOURIER, would test whether or not low-density lipoprotein cholesterol (LDL‑C) is a viable surrogate for cardiovascular outcomes for evolocumab. The committee agreed that this trial would give useful data on the direct effect of evolocumab on cardiovascular disease.